Clinical Trials Logo

Disease, Hodgkin clinical trials

View clinical trials related to Disease, Hodgkin.

Filter by:
  • None
  • Page 1

NCT ID: NCT01196208 No longer available - Clinical trials for Lymphoma, Non-Hodgkin

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide the option of brentuximab vedotin treatment to eligible patients in studies SGN35-005 and C25001

NCT ID: NCT01100502 Completed - Disease, Hodgkin Clinical Trials

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Start date: April 30, 2010
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).

NCT ID: NCT01060904 Completed - Disease, Hodgkin Clinical Trials

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Start date: January 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety profile of brentuximab vedotin in combination with multi-agent chemotherapy in treatment-naive Stage IIa or IIb-IV Hodgkin lymphoma. It is a phase 1, two-arm, open-label dose escalation study designed to define the maximum tolerated dose, pharmacokinetics, immunogenicity and anti-tumor activity of brentuximab vedotin in combination with frontline therapy.

NCT ID: NCT01026415 Completed - Neoplasms Clinical Trials

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Start date: December 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion. The study will also assess blood drug levels in patients with renal or hepatic impairment (special populations).

NCT ID: NCT01026233 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Start date: January 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (SGN-35) in patients with CD30-positive cancers. The study will assess electrical activity of the heart before and after brentuximab vedotin administration. Patients who have stable or improving disease may receive up to 1 year of brentuximab vedotin treatment.

NCT ID: NCT00947856 Completed - Clinical trials for Lymphoma, Non-Hodgkin

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

Start date: July 2009
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.

NCT ID: NCT00848926 Completed - Disease, Hodgkin Clinical Trials

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Start date: February 2009
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.

NCT ID: NCT00649584 Terminated - Clinical trials for Lymphoma, Non-Hodgkin

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

Start date: March 2008
Phase: Phase 1
Study type: Interventional

This study will examine the safety profile of SGN-35 alone and in combination with gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of patients.

NCT ID: NCT00430846 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

Start date: November 2006
Phase: Phase 1
Study type: Interventional

Phase I study to define the safety profile and pharmacokinetic parameters of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies. This is a single-arm, open-label, Phase I dose escalation study designed to define the MTD, PK, immunogenicity and anti-tumor activity of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies.